Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

438
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
438
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

400
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
400
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

281
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
281
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

266
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

689
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
689
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

443
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
443

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same author

Physical inactivity and other cardiovascular risk factors in patients with psoriatic arthritis: Do we really "kill two birds with one stone" by managing inflammation?

Reumatologia·2026
Same author

Prevalence and clinical risk factors for methotrexate intolerance in patients with juvenile idiopathic arthritis.

ARP rheumatology·2026
Same author

Editorial: Understanding scleroderma: symptoms, causes, treatment options, and advanced diagnostic techniques.

Frontiers in immunology·2025
Same author

Terminologies and definitions used to classify patients with osteoarthritis: a scoping review.

BMC rheumatology·2025
Same author

Do Patients with Rheumatoid Arthritis Have an (In)Adequate Level of Physical Activity? A Latent Class Analysis Approach.

Life (Basel, Switzerland)·2025

Related Experiment Video

Updated: Mar 2, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

663

Managing refractory cryoglobulinemic vasculitis: challenges and solutions.

Predrag Ostojic1, Ivan R Jeremic1

  • 1Institute of Rheumatology, School of Medicine, University of Belgrade, Belgrade, Serbia.

Journal of Inflammation Research
|May 17, 2017
PubMed
Summary

Cryoglobulinemia is a rare condition often linked to Hepatitis C virus (HCV). Treatment involves antivirals and immunosuppressants for HCV-related cryoglobulinemic vasculitis (CryoVas), with rituximab as a key therapy.

Keywords:
cryoglobulinemiatreatmentvasculitis

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Related Experiment Videos

Last Updated: Mar 2, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

663
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.7K

Area of Science:

  • Immunology
  • Rheumatology
  • Hepatology

Background:

  • Cryoglobulinemia is a rare condition, potentially isolated or secondary to other diseases.
  • Mixed cryoglobulinemia (types II and III) can lead to cryoglobulinemic vasculitis (CryoVas) due to immune complex deposition.
  • Hepatitis C virus (HCV) is implicated in up to 90% of mixed cryoglobulinemia cases.

Purpose of the Study:

  • To summarize the understanding of cryoglobulinemia, particularly cryoglobulinemic vasculitis (CryoVas).
  • To outline current therapeutic strategies for HCV-related and non-HCV-related CryoVas.
  • To highlight the role of rituximab and other emerging therapies.

Main Methods:

  • Literature review of cryoglobulinemia and cryoglobulinemic vasculitis.
  • Analysis of clinical manifestations and diagnostic markers, including HCV RNA detection.
  • Evaluation of treatment outcomes for various therapeutic approaches.

Main Results:

  • CryoVas commonly presents with skin lesions, neuropathy, glomerulonephritis, and arthralgia.
  • HCV is a major driver of mixed cryoglobulinemia.
  • Antiviral therapy combined with immunosuppressants (including rituximab) is effective for HCV-related CryoVas.

Conclusions:

  • HCV-related cryoglobulinemic vasculitis requires a multi-faceted treatment approach.
  • Rituximab is an effective second-line therapy and can spare glucocorticoids.
  • Management strategies should be tailored to disease severity and organ involvement.